Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617023 | 1.00 | PLA2G2C (0.40) | PLA2G2CFOLH1NAALAD2RIMKLAGABRP | |
| SCHEMBL891048 | 0.83 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLAGABRPGABRD | |
| SCHEMBL7352206 | 0.82 | DPP4 (0.38) | NFKB1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL11363514 | 0.82 | DPP4 (0.38) | NFKB1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL27880264 | 0.81 | FOLH1 (0.37) | FOLH1NAALAD2RIMKLAGABRPGABRD | |
| SCHEMBL28779839 | 0.81 | PLA2G2C (0.39) | PLA2G2CFOLH1NAALAD2RIMKLAGABRP | |
| SCHEMBL4461170 | 0.80 | LMNA (0.39) | FOLH1NAALAD2RIMKLAGABRPGABRD | |
| SCHEMBL21724390 | 0.79 | PLA2G2C (0.45) | PLA2G2CFOLH1NAALAD2RIMKLAGABRP | |
| SCHEMBL3381661 | 0.79 | SMN1; SMN2 (0.38) | NFKB1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL1970042 | 0.79 | ANPEP (0.48) | FOLH1NAALAD2RIMKLAGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096908-A | Method for preparing guanidinoacetic acid by fermentation | 赢创运营有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115803442-A | Method for preparing guanidinoacetic acid by fermentation | 赢创运营有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114867861-A | Method for producing guanidinoacetic acid by fermentation | 赢创运营有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-107002027-B | Microorganism of corynebacterium genus having ability to produce L-arginine and method for producing L-arginine using the same | CJ第一制糖株式会社 | 2021-05-28 | — | — | CN | claimed |
| CN-112386503-A | Microneedle mask containing active peptides and preparation method thereof | 上海可米日化股份有限公司 | 2021-02-23 | — | — | CN | claimed |
| CN-112386502-A | Microneedle mask containing cell growth factors and preparation method thereof | 上海可米日化股份有限公司 | 2021-02-23 | — | — | CN | claimed |
| US-10626426-B2 | Microorganism of genus Corynebacterium having an ability to produce L-arginine and a method for producing L-arginine using the same | CJ CHEILJEDANG CORPORATION (KR) | 2020-04-21 | — | — | US | claimed |
| US-20170361130-A9 | STABILIZED AND SOLUBILIZED DRUG FORMULATION FOR TOPICAL APPLICATION AND TRANSDERMAL EFFICACY FOR COSMETIC IMPROVEMENT AND METHODS OF FORMULATION | TRANSDERMAL CORP. | 2017-12-21 | — | — | US | claimed |
| US-20170304187-A1 | EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections | DESAI, KETAN | 2017-10-26 | — | — | US | claimed |
| US-20150157728-A1 | STABILIZED AND SOLUBILIZED DRUG FORMULATION FOR TOPICAL APPLICATION AND TRANSDERMAL EFFICACY FOR COSMETIC IMPROVEMENT AND METHODS OF FORMULATION | MODI PANKAJ (CA) | 2015-06-11 | — | — | US | claimed |
| US-20120315235-A1 | EMU OIL IN COMBINATION WITH OTHER ACTIVE INGREDIENTS FOR TREATING SKIN IMPERFECTIONS | DESAI, KETAN | 2012-12-13 | — | — | US | claimed |
| EP-4393939-A1 | LYSE VARIANT AND METHOD FOR PRODUCING L-ARGININE BY USING SAME | CJ CheilJedang Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199699-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | GLO PHARMA, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-118159551-A | LysE variants and methods of producing L-arginine using the same | CJ第一制糖株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20030113899-A1 | Method for producing L-arginine | AJINOMOTO CO., INC. (JP) | 2003-06-19 | — | — | US | disclosed |
| CN-1370236-A | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport | BASF AG (DE) | 2002-09-18 | — | — | CN | disclosed |
| CN-1370235-A | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | BASF AG (DE) | 2002-09-18 | — | — | CN | disclosed |
| CN-1370234-A | Corynebacterium glutamicum genes encoding proteins involved in homeostasis and adaptation | BASF AG (DE) | 2002-09-18 | — | — | CN | disclosed |
| EP-1033407-A1 | PROCESS FOR CONSTRUCTING AMINO ACID-PRODUCING BACTERIUM AND PROCESS FOR PRODUCING AMINO ACID BY FERMENTATION METHOD WITH THE USE OF THE THUS CONSTRUCTED AMINO ACID-PRODUCING BACTERIUM | Ajinomoto Co., Inc. (JP) | 2000-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | PLA2G2C 456/4885FOLH1 1047/4885NAALAD2 594/4885 |
| US-20240199699-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | CHRNA1, CHRNG, CHRNB1 | PLA2G2C 2488/4885FOLH1 3047/4885NAALAD2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.